{Reference Type}: Journal Article
{Title}: Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial.
{Author}: Kooshki A;Memarzadeh MR;Rakhshani MH;Akbarzadeh R;Tofighiyan T;Foroumandi E;
{Journal}: Avicenna J Phytomed
{Volume}: 14
{Issue}: 4
{Year}: 2024 Jul-Aug
暂无{DOI}: 10.22038/AJP.2023.23447
{Abstract}: <B>UNASSIGNED: </B>This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.<BR><B>UNASSIGNED: </B>Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.<BR><B>UNASSIGNED: </B>Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.<BR><B>UNASSIGNED: </B>Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.